Skip to content

Fenofibrate capsule bioequivalence

Bioequivalence study of the Fenofibrate 200 mg capsule manufactured by Tehran Darou Pharmaceutical Company vs. AbbVie Pharmaceutical Company in healthy volunteers.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130313012810N65
Enrollment
24
Registered
2025-09-26
Start date
2025-09-29
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence study in healthy volunteers.

Interventions

Intervention 1: Intervention group1: In this group, volunteers are given a single oral dose of Fenofibrate 200-mg capsules manufactured by Tehran Darou Pharmaceutical Company. In each period, 12 of 24

Sponsors

Tehrandarou Company
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form. All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw

Exclusion criteria

Exclusion criteria: History of allergic or adverse reaction to Fenofibrate or any similar product Volunteers with blood pressure less than 90/60mm Hg or higher than 140/90mm Hg. Individuals who have donated whole blood during the last 2 months Individuals who have donated blood components, such as platelets, within the past 2 weeks

Design outcomes

Primary

MeasureTime frame
Plasma concentration of the drug. Timepoint: 16 sampling time included pre-dose (time 0) and at the following hours post-dose: 1, 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24, 48, and 72h. Method of measurement: Liquid Chromatography with tandem mass spectrometry (LC-MS-MS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Hamidi

Zanjan University of Medical Sciences

hamidi@hidapharma.com+98 24 3342 0651

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026